Dimericon Therapeutics
PrivateLast Round
Seed
May 1, 2023
Total Funding Raised
$14M
Company Overview
Dimericon Therapeutics is a biotechnology company that develops precision oncology therapeutics targeting intracellular protein-protein interactions using crosslinked helix dimer modalities.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Dimericon Therapeutics Comparables
Compare Dimericon Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| A-Alpha Bio | 79% | |
| SPIMA Therapeutics | 75% | |
| PRISM BioLab Co., Ltd. | 73% | |
Dimericon Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | May 1, 2023 |
Dimericon Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioMedPartners | Seed |
| AbbVie Ventures | Seed |
| CARMA FUND | Seed |
| High-Tech Gründerfonds | Seed |
| Blood Cancer United | Seed |
Dimericon Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Dimericon Therapeutics's valuation, stock price, and market status.